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Abstract  
Background 
A review of economic evaluations of public health interventions assessed by NICE between 
2005 and 2010 found 85% were cost-effective.1 With significant pressure on budgets the role 
of economics in securing funding remains important. This study updates the earlier analysis.  
Methods 
Economic evaluations carried out between 2011 and 2016 were categorised: cost utility 
analysis (CUA, cost-effectiveness analysis(CEA), cost benefit analysis(CBA) and cost 
consequences analysis(CCA). Cost-effectiveness estimates were analysed and compared 
with Owen et al 2011.1  
Results 
Of forty-three guidelines examined, 23 used CUA for specific interventions yielding 138 
base-case ICER estimates, 11 used CUA IRUDWKUHVKROGRUµZKDWLI¶DQDO\VLV, 1 used CEA, 3 
used CCA, 1 used CBA and CUA and 1 used CEA and CUA, 5 did not require economic 
modelling. Compared with the earlier period, the median ICER for the 138 estimates was 
substantially higher (£7,843 versus £1,053) and there was greater variability (a higher 
proportion in the later period was cost saving, but a higher proportion was also over £20,000 
per QALY).  
Conclusions 
Nearly two-thirds (63%) of public health interventions assessed were cost-effective. 
However, increased variability in estimates highlights the importance of assessing cost-
effectiveness to ensure good use of scarce resources.  
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Background 
In 2011, Owen et al analysed 200 base-case cost-effectiveness estimates of public health 
interventions considered in 21 public health guidelines developed by the National Institute for 
Health and Care Excellence (NICE).1 They concluded that the majority of public health 
interventions assessed by NICE were estimated to be cost-effective and a significant minority 
(15%) were cost saving. It is timely to update the analysis now that 61 public health 
guidelines have been produced at the time of writing.  
The funding for public health interventions has changed since the original Owen et al paper, 
particularly because of the Health and Social Care Act 2012. Local authorities are now 
responsible for improving public health and reducing health inequalities.2 The role of 
economics in securing funding remains important, with Directors of Public Health requiring 
evidence on cost-effectiveness.3 The budget available for local authorities for improving 
public health in England is notably less than that for treating ill-health ± the 2016/17 
allocation for public health is £3.38billion4, compared with the £106.8billion budget for the 
National Health Service (NHS).5   
Potential topics for NICE guidelines are first considered by the NICE topic oversight group, 
taking into account the existence of NICE-accredited guidance and the priority of the topic 
according to commissioners, professional organisations and service users. NICE then 
discusses identified topics with the Department of Health and Public Health England (for 
public health guidelines) and NHS England (for clinical guidelines) and a prioritised list is 
agreed. 6  
1,&(¶VDSSURDFKWRDVVHVVLQJthe cost-effectiveness of public health interventions remains 
relatively unchanged, although the guidance on public health guideline development has been 
superseded by a unified guidelines manual.6 This manual sets out the reference case for 
economic evaluation and advises on the use of economic evidence in guideline development. 
For interventions with costs and health outcomes in NHS settings, the reference case 
stipulates that the type of economic evaluation must be a cost-utility analysis (CUA). Despite 
much discussion in the literature7,8WKH³WKUHVKROG´EHORZZKLFKLQWHUYHQWLRQVDUHJHQHUDOO\
considered to be cost-effective remains at £20,000 per quality adjusted life year (QALY). For 
interventions with health and non-health outcomes in public sector and other settings, the 
reference case additionally lists cost-effectiveness analysis (CEA), cost-consequences 
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analysis (CCA) and cost-benefit analysis (CBA) as potential types of economic evaluation.6 
The budget available to Local Government would appear to be insufficient to accommodate 
all interventions identified as cost-effective.  
This study updates the original analysis (Owen 2011)1 for interventions where the 
incremental cost-effectiveness ratio (ICER) estimates were available. In addition, it aimed to 
explore the different types of economic evaluation used in NICE Public Health guidelines. 
 
Methods 
Economic evaluations undertaken for every NICE public health guideline published between 
2011 and 2016 were examined. Each economic evaluation was categorised by type: CUA, 
CEA, CBA and CCA. It was noted that some guidelines may use more than one type of 
analysis. CUAs were further categorised by those with base-case estimates, and those that 
only used WKUHVKROGRU³ZKDWLI´DQDO\VLVZKHUHWKHVSHFLILFFRVWDQGRUHIIHFWLYHQHVVRIDQ
intervention is not known. 
The NICE guideline manual states that the comparator for public health interventions should 
EH³LQWHUYHQWLRQVURXWLQHO\GHOLYHUHGLQWKHSXEOLFVHFWRUincluding those regarded as best 
practice.´ 6 In practice, the evidence base for public health interventions is often limited, and 
WULDOVWKDWUHSRUW³EHVWSUDFWLFH´DVDFRPSDUDWRUPD\KDYHGLIIHUHQWLQWHUSUHWDWLRQVRIZKDW
this is. )XUWKHUPRUH³EHVWSUDFWLFH´LVQRWQHFHVVDULO\FRQVLVWHQWDFURVV(QJODQGVLQFHSXEOLF
health is funded at the local rather than national level. To compare an intervention against all 
possible comparators would require network meta-analyses which is frequently not possible 
because of a paucity of information and heterogeneity in the study population, comparators 
and outcomes. The economic evaluations considered in NICE public health guidelines and in 
this study are therefore pairwise comparisons between one intervention and comparator, 
usually based on a single study or meta-analysis. Each evaluation represents a specific case 
study and is not necessarily generalizable to all populations and settings, so for some 
guidelines there are multiple interventions which seem similar.  
Cost utility analyses 
For interventions with base-case estimates, the analysis performed by Owen et al (2011)1 was 
repeated. The incremental cost-effective ratios (ICERs) reported for each intervention were 
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extracted from the model reports and summarised by topic and according to one of five 
categories: cost saving (costs less and produces more benefits than the comparator); between 
£0 and less than £20,000 per QALY; between £20,000 and less than £30,000 per QALY; 
£30,000 per QALY and above; and dominated (costs more and produces less benefit than the 
comparator). The number of ICERs that were cost saving or dominated were counted. The 
median ICER for interventions in each of the remaining three categories was calculated. This 
approach provided consistency with the original paper and enabled an updated 
comprehensive list of the cost-effectiveness of public health interventions to be produced. 
The overall median was also calculated and compared with that of the earlier period. The 
findings from the updated analysis were compared with those from the 2011 analysis using 
comparisons between median ICERs and proportion of interventions cost-saving and cost-
effective. The reasons for differences in results, and the implications of these were explored.  
Other types of economic evaluation  
We reviewed how guidelines were developed where specific CUA evidence of interventions 
was unavailable. We examined interventions where CEA, CCA and CBA have been used, to 
understand scenarios in which these types of economic evaluation are appropriate and how 
NICE committees consider this evidence in developing guidelines.  
Results 
Forty-three guidelines were published between the publication of Owen et al (2011)1, and 
September 2016. Twenty-three of these guidelines used CUA for specific interventions and 
provided 138 base-case ICER estimates. A further 11 guidelines used CUA only for a 
WKUHVKROGRUµZKDWLI¶DQDO\VLV2QHJXLGHOLQHXVHGDCEA, and three guidelines used CCA. 
One guideline used CBA in addition to CUA and one used CEA in addition to CUA. Five 
guidelines did not require economic modelling.   
CUA base-case ICERs  
The 2011-16 ICERs are compared to those from the original analysis (Owen 2011)1 in Table 
1. The proportion of interventions which are cost-effective at £20,000/QALY has decreased 
from 85.5% to 63%, but the proportion which are cost-saving has increased. The proportion 
which are dominated has decreased, but the proportion which are not cost-effective at 
£20,000/QALY or £30,000/QALY has increased. The median ICERs for interventions with 
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ICERs ranging from £0-£20,000/QALY, £20,000-£30,000/QALY and over £30,000/QALY 
have all increased. A summary of the ICERs by guideline is presented in Table 2. 
³What if´ analysis  
Eleven guidelines used cost-utility analysis, but used a ³WKUHVKROG´RU³ZKDW-LI´VFHQDULR
analysis framework alone and therefore do not report specific ICERs. This approach 
considers at what cost and effectiveness interventions would be cost-effective rather than 
calculating base-case ICERs for specific interventions. It is similar to a sensitivity analysis, 
but where there is no base-case ICER. It is used when the value of one or more of the 
parameters is unknown - several likely possible values of the parameters are chosen, and the 
cost-effectiveness is worked out. The idea is to find out how big the effect or how low the 
cost would have to be for the intervention to be borderline cost-effective.  
CEA 
One guideline covering contraceptive services for under 25s (PH51) used CEA, reporting 
outcomes in natural units (pregnancy or abortion averted).9 The use of QALYs was not 
appropriate for this guideline because the interventions aimed to delay or prevent conception 
and NICE does not attempt to place a value on potential life in the future. The analysis 
considered several interventions, some of which resulted in net cost savings and which 
provided a clear economic case for recommending contraceptive services for young people.10  
CCA 
Three guidelines used CCA alone, reporting the costs and outcomes for intervention and 
comparator without quantifying a comparison: NG44 for community engagement 
programmes11, NG48 for oral health promotion programmes in nursing homes12 and PH56 
for interventions to increase the uptake of vitamin D supplements.13 In each case, this 
analysis was chosen because there was a lack of evidence linking the outcomes included in 
the effectiveness studies with health related quality of life, and there were other important 
dimensions to take into account.  
CBA 
One guideline, for unintentional injuries on the road, used CBA, in addition to cost-utility 
analysis. CBA was included because the interventions under consideration would be funded 
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by the transport sector, whose preferred form of economic evaluation is cost benefit 
analysis.14  
Discussion 
Main finding of this study 
This study found that a smaller proportion of interventions were estimated to be cost-
effective at £20,000/QALY in this analysis than in 2011. This should not be interpreted as 
public health interventions becoming less cost-effective, but more an indication of differences 
between the two time-periods in the types of interventions and topic areas assessed - the 
topics that were chosen earlier may have been those that were (on average) more cost-
effective. When we consider the broad remit of public health interventions that could be 
funded, we see that there is wide variation in their cost-effectiveness. Decision makers need 
to be aware of this variation in order to maximise health gain within a limited budget. It is 
imperative that decision makers carefully consider the costs and benefits of public health 
interventions when making funding decisions.  
Clinical interventions often have high incremental costs as a result of new technologies, 
whereas public health interventions tend to have incremental lower costs per person. This 
may be because the interventions are delivered on a population level and so the cost is shared 
between a large group and the benefit only applies to a few individual, or may be because the 
interventions have relatively low costs. With relatively low incremental costs and QALYs, 
the ICERs of public health interventions are very sensitive to small changes in intervention 
costs or effectiveness, which is why seemingly similar interventions can have very different 
results. Decision makers and funders therefore need to carefully consider the costs and 
benefits of interventions they commission, either by comparing the interventions to those 
with published ICERs (such as these here) or by evaluating the new programme.  
In June 2015 the Government announced a cut of £200 million in the 2015/16 public health 
grant to local authorities. Further cuts of £77 million and £84 million are planned for 2016/17 
and 2017/18.15  There is growing evidence that these significant financial pressures are 
leading local authorities to disinvest in highly cost-effective non-statutory public health 
services such as local stop smoking services.16 The likely knock-on effect is that other public 
services, particularly the NHS, will experience increased pressure and higher costs, though 
this may not occur immediately or even within a couple of years of the reduction in services. 
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Cost effectiveness in public health optimises over the long term whereas commissioning 
cycles operate over very short time periods. The benefits of a healthy lifestyle may not be 
seen for decades, but will add many additional years to the lives of individuals and give 
higher health related quality of life. This raises a difficult but important question about the 
link between affordability and cost-effectiveness. Our current analysis found that nearly two-
thirds of the public health interventions studied in cost-utility analyses were cost-effective or 
cost-saving according at a threshold of £20,000 and as such provide excellent value for 
money. However, for Local Authorities with limited budgets, funding all these interventions 
may not be affordable. Research is needed to understand whether current disinvestment in 
non-statutory public health services reduces population net health benefit long-term.   
7KHSUHVHQWDQDO\VLVLGHQWLILHGHOHYHQJXLGHOLQHVLQIRUPHGE\µZKDWLI¶ (or so-called 
µWKUHVKROG¶ analyses. Although not reported by Owen and colleagues, there were only three 
guidelines in the time period up to 2011 that necessitated such an approach. This finding 
suggests that over time, NICE has received an increasing number of referrals for 
interventions and behaviours for which there are significant gaps in the evidence base. 
Threshold analyses are also useful where costs and effects vary widely between interventions 
and settings (but are known locally to decision makers).  
We provide cases where methods other than CUA have been used. The decision to use the 
results of a cost benefit analysis in transport-related interventions was justified, even though 
the conclusions from cost utility analysis were different  due to a difference in perspective.  
The CUA took a public sector perspective and accounted for all QALYs and medical, police, 
local authority and department for transport costs invested or saved. The cost-benefit analysis 
was from a broader societal perspective and accounted for medical and human costs saved 
and lost output saved.   
The role of cost consequences analysis in developing recommendations is, arguably, less 
straightforward.  When there is more than one outcome of interest, the relative importance of 
the outcomes is unclear and may differ from one person to another. There are other 
difficulties too, for example, the committee for community engagement found it difficult to 
make a general statement about whether community engagement provides good value for 
money based on the very specific and small number of case studies used in the analysis. 
However, others take the view that cost consequences analysis is easier to understand for the 
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purposes of decision making and resource allocation because decision makers are able to 
select the components most relevant to their perspective.17,18   
What is already known on this topic 
In 2011, Owen et al estimated that most public health interventions considered in NICE 
guidelines were cost-effective. Others too have found that public health interventions are 
cost-effective, and that investing in prevention saves money in the future.19  
The challenges of economic modelling in public health are well known.20 The suitability of 
the QALY outcome is widely discussed, and its limitations recognised. The role of other 
forms of economic analysis, in particular cost consequences analysis is much debated, and its 
application in decision making warrants further investigation.18, 21-23 
What this study adds 
This paper provides an updated comprehensive source of the cost-effectiveness of public 
health interventions considered in NICE guidance and can be used by decision makers to 
inform funding decisions. While the general tenor of the results follows a similar path 
covered by the 2005 to 2011 paper, the later results show a greater spread of the distribution 
of the ICERs, and quite a substantial increase in the overall median ICER. This leads into 
discussion about why ICERs vary, and the importance of decision makers carefully 
considering the costs and benefits of public health interventions. The use of CEA and CCA 
demonstrate the challenges that still remain in applying CUA analysis to the assessment of 
public health interventions. We hope that this contributes to wider discussions about the cost-
effectiveness of public health interventions generally, and the methods used for economic 
evaluation in public health.  
Limitations of this study 
Although this study represents a comprehensive list of the cost-effectiveness of public health 
interventions studied in NICE guidelines, it represents a subset of all public health 
interventions. This is because the interventions assessed by NICE are determined by a topic 
referral process which was described earlier, the number of topics that can be assessed by 
NICE is limited by the resources available, and the broad scope of public health makes for a 
substantial number of potential interventions.  
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Table 2 shows that the topics referred to NICE between 2011-2016 covered a diverse range 
from interventions targeting individual lifestyle behaviours such as smoking, alcohol misuse 
and physical inactivity to those µtargeting¶ overall population wellbeing such as looked after 
children, cold homes and community engagement. We have been unable to carry out any 
form of regression analysis to isolate the determinants of cost-effectiveness because of the 
enormous range of possible determinants and the fragmentary nature of the cost-effectiveness 
analyses in the literature. 
This study includes multiple similar interventions within several guidelines, such as those for 
smoking cessation in secondary care (PH48) and smoking harm reduction (PH45). Including 
multiple interventions with similar ICERs may have skewed the distribution of the data - in 
these examples all interventions have relatively low or dominant ICERs. In contrast, cold 
homes (NG6) and skin cancer prevention (PH32) have multiple interventions with very high 
ICERs. This is a feature of the availability of data to inform analyses for the guidelines and 
should be noted as a limitation. By calculating the median rather than the mean ICER we 
hoped to mitigate the impact of this skew.    
It was not possible for us to compare the cost-effectiveness of all NICE public health 
interventions in all guidelines, as not all include QALYs as an outcome. Even where QALYs 
were reported, care must be taken in making direct comparisons. It is likely that economic 
analyses will vary in the extent to which they have been able to fully capture the costs and 
consequences arising from complex, multi-faceted public health interventions.  
A further limitation involves the comparator. In some cases, such as in smoking cessation, a 
number of interventions have in the past all been compared with a background quit rate 
³doing nothing´, and most were cost saving. A new intervention might well be cost-
effective compared with no intervention, but may be dominated by an existing intervention. It 
is therefore imperative that decision makers ensure that they consider economic analysis that 
is similar to their decision problem in terms of population, intervention and comparator.  
Finally, we note the limitation that adjustment for costs and standard of living adjustments for 
the real-money value of QALYs have not been made.  
Conclusion 
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Although many public health interventions are cost-effective or even cost-saving, there is a 
large variation in the cost-effectiveness of public health interventions, and some do not 
represent good value for money. In order to maximise health gain within a limited budget, it 
is imperative that decision makers and those funding public health understand the costs and 
benefits associated with different interventions.  
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Table 1 Number (%) and median values of ranges of the estimated incremental cost per 
QALY for public health interventions assessed and published by NICE between 2006 
and 2016 
 Cost 
saving 
£0-
<£20,000 
£20,000-
£30,000 
>£30,000 Intervention 
was 
dominated 
  
Published 2011-2016 Median* Interquartile 
range of 
medians 
Number 
(%) 
35 (25) 53 (38) 4 (3) 43 (31) 3 (2)   
Median N/A £4,830 £25,306 £188,301 N/A £7,843 £75 - 
£61,814 
Published 2006-2010 Median* Interquartile 
range of 
medians 
Number 
(%) 
30 (15) 141 (70.5) 7 (3.5) 11 (5.5) 11 (5.5)   
Median N/A £1,030 £25,150 £90,786 N/A £1,053  £149 - 
£6587 
*The median of the whole sample consists of the middle observation for that time-period, 
where the dominating (cost-saving) ICERs are counted at the low end and the dominated 
ICERs are counted at the high end of the ICER distribution.  
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Table 2 Value of incremental cost-effectiveness estimates for public health interventions 
assessed and published by NICE between 2011-2016 
 
Guidance topic & interventions  Comparator 
 cost/QALY 
(£)  
NG30: Oral health promotion: general dental practice 
 
one-to-one counselling to parents of children aged 5 years at 
average risk 
caries in socio-economically deprived areas in Northwest 
England usual care 
          
£163,558  
One-to-one counselling to parents of children aged 5 years at high risk 
caries in socio-economically deprived areas in Northwest England dominant  
Dental hygienists OH prog for children aged 12 years at 
average risk usual care 
                   
£14,408  
Dental hygienists OH prog for children aged 12 years at high risk dominant  
NG32: Older people: independence and mental wellbeing 
 
internet and computer training usual care £15,962  
Friendship programme 
 
dominant  
PH27: Weight management in pregnancy 
 
weight management interventions 
conventional postnatal 
care 
                     
£9,096  
PH30: Unintentional injuries in the home 
 
Free smoke alarms programme no intervention £23,046  
PH35: Type 2 diabetes: pop and comm 
 
broad dietary education/cooking skills no intervention £878  
new food retail outlet no intervention dominated  
multicomponent small scale no intervention £562  
large scale region-wide multi component no intervention dominant  
PH38:Type 2 diabetes: high risk 
 
/3'6+E$FLQWHQVLYHLQWHUYHQWLRQ 
Vascular Checks 
(without intervention) 
             
£12,042  
/3'6+E$FLQWHQVLYHLQWHUYHQWLRQ 
Vascular Checks 
(without intervention) 
                   
£11,169  
/3'6+E$FLQWHQVLYHLQWHUYHQWLRQ 
Vascular Checks 
(without intervention) 
                   
£11,376  
/3'6)3*PPRO/LQWHQVLYHLQWHUYHQWLRQ 
Vascular Checks 
(without intervention) 
                     
£7,057  
/3'6+E$FLQWHQVLYHLQWHUYHQWLRQ 
Vascular Checks (with 
intervention) 
                   
£14,154  
/3'6+E$FLQWHQVLYHLQWHUYHQWLRQ 
Vascular Checks (with 
intervention) 
                   
£15,192  
/3'6+E$FLQWHQVLYHLQWHUYHQWLRQ 
Vascular Checks (with 
intervention) 
                   
£19,259  
/3'6)3*PPRO/LQWHQVLYHLQWHUYHQWLRQ 
Vascular Checks 
(without intervention) 
                   
£13,440  
PH38:Type 2 diabetes: South Asians age 25-39 years  
 
/3'6+E$FLQWHQVLYHLQWHUYHQWLRQ 
Vascular Checks 
(without intervention) dominant  
PH40: Social emotional wellbeing early years 
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weekly home visits no intervention 
                   
£85,097  
sure start - 1 year no intervention dominant  
sure start - 3 year no intervention £15,148  
sure start - 5 year no intervention dominant  
PH41: Physical activity: walking and cycling 
 
multi-component cycling demonstration  no intervention £4,830  
multicomponent sustainable travel towns no intervention £997  
travelsmart (continuous risk) no intervention £300  
travel smart (step risk) no intervention £2,500  
pedometer 4 week baker (continuous risk) no intervention £2,903  
pedometer 4 week baker (step risk) no intervention £9,448  
pedometer sustained Baker (continuous risk) no intervention £1,731  
pedometer sustained Baker (step risk) no intervention £7,817  
pedometer Merom (continuous risk function) no intervention £1,530  
pedometer Merom (step risk function) no intervention £1,995  
PH43: Hep C testing 
  
dried blood spot testing in addiction services not offering DBS £14,632  
PH43: Hep B & C testing 
 
 
DBS in prison not offering DBS 
                
£59,418  
GP education and paid targeted testing of ex IDUs no intervention £13,877  
PH44: physical activity: brief advice for adults in primary care 
brief advice for one year no brief advice  £1,730  
PH45: Smoking: Harm reduction 
 
CDTQ + NCP + generic support no treatment 
                 
£668  
CDTQ + NCP + specialist support no treatment £2,294  
CDTQ + NCP no treatment £544  
CDTQ + generic support no treatment dominant  
CDTQ + specialist support no treatment £437  
CDTQ no treatment dominant  
Abrupt + NCP substitute + generic support no treatment £2,836  
Abrupt + NCP substitute + specialist support no treatment £4,280  
Abrupt + NCP substitute no treatment £7,388  
Temporary abstinence + NCP + generic support no treatment £765  
Temporary abstinence + NCP + specialist support no treatment £2,458  
Temporary abstinence + NCP no treatment £7,843  
Temporary abstinence + generic support no treatment £706  
Temporary abstinence + specialist support no treatment £8,464  
Temporary abstinence no treatment 
no benefit, 
no cost  
Reduce + NCP + generic support no treatment £765  
Reduce + NCP + specialist support no treatment £2,458  
Reduce + NCP no treatment £7,843  
Reduce + generic support no treatment £706  
Reduce + specialist support no treatment £8,464  
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Reduce no treatment dominant  
PH48: Smoking cessation secondary care 
 
high intensity behavioural intervention for pregnant women 
Hartman 
low intensity 
behavioural dominant  
high intensity behavioural intervention for pregnant women 
Domelas usual care 
                         
£634  
high intensity behavioural intervention for pregnant women 
Hegaard  usual care 
                   
£15,281  
high intensity behavioural intervention for pregnant women 
Ershoff usual care dominant  
conditional incentives for pregnant women Higgins unconditional incentives £3,076  
conditional incentives for pregnant women Donatelle unconditional incentives £5,149  
conditional incentives for pregnant women Heil unconditional incentives £3,306  
behavioural + pharmacological for PTSD patients usual care dominant  
behavioural + pharmacological for PTSD patients usual care £6,407  
high intensity behaviouraL + pharmacological for pre-
operative patients Moller 
low intensity 
behavioural dominant  
high intensity behaviouraL + pharmacological for pre-
operative patients Lindstrom 
low intensity 
behavioural dominant  
high intensity behavioural for COPD BTS brief advice dominant  
high intensity behavioural + pharmacological for COPD 
Tonnesen 
low intensity 
behavioural dominant  
pharmacological for COPD Borglykke usual care dominant  
 High intensity behavioural + pharmacological for cardiac de 
Busk brief advice dominant  
high intensity behavioural for cardiac Quist 
low intensity 
behavioural dominant  
Behavioural + pharmacological for cardac Taylor usual care dominant  
High intensity behavioural for cardiac Henrrikus brief advice dominant  
pharmacological for general inpatients Miller 
low intensity 
behavioural dominant  
pharmacological for hospital employees Dalsgaro 
placebo + low intensity 
behavioural dominant  
Total smoke free policy -indoor and outdoor Gadomski Indoor smokefree policy dominant  
PH50: Domestic violence and abuse: multi-agency working 
 
incidence reduction - independent domestic violence advisors no IDVA dominant  
harm reduction - cognitive trauma therapy - battered women CTT-BW dominant  
PH54: Physical activity exercise referral schemes 
 
ERS usual care £88,742  
PH31: Unintentional injuries on the road 
 
mixed priority routes no intervention £304,823  
mandatory 20mph zones LOW CASUALTIES no intervention £457,762  
mandatory 20mph zones HIGH CASUALTIES no intervention £89,700  
advisory 20mph zones no intervention £22,952  
NG34: sunlight exposure: risks and benefits 
 
living with the sun' do nothing £312,744  
photo-aging 
 
£316,968  
tailored message 
 
£16,859  
mass media  
 
dominant  
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text messages 
 
£65,945  
NG6: Cold homes 
  
energy efficiency COPD none £28,324  
energy efficiency HD none £157,137  
energy efficiency CMD none £394,556  
energy efficiency age 65+ none £157,661  
energy efficiency low income none £275,896  
fuel subsidy COPD none £39,437  
fuel subsidy HD none £188,301  
fuel subsidy CMD none £509,205  
fuel subsidy age 65+ none £204,076  
fuel subsidy low income none £358,089  
energy efficiency+ fuel subsidy COPD none £33,771  
energy efficiency+ fuel subsidy HD none £174,467  
energy efficiency+ fuel subsidy CMD none £452,154  
energy efficiency+ fuel subsidy age 65+ none £180,456  
energy efficiency+ fuel subsidy low income none £317,927  
PH28: Looked after children - Transition support services 
 
Georgiades (2005) men 
usual care/ no 
intervention dominant  
Georgiades (2005) women 
usual care/ no 
intervention dominant  
Lemon et al (2005) men 
usual care/ no 
intervention £2,573,542 
Lemon et al (2005) women 
usual care/ no 
intervention dominated 
Lindsey & Ahmed (1999) men 
usual care/ no 
intervention dominant  
Lindsey & Ahmed (1999) women 
usual care/ no 
intervention dominant  
Scannapieco (1996) men 
usual care/ no 
intervention dominant  
Scannapieco (1996) women 
usual care/ no 
intervention dominant  
PH32: Skin cancer prevention 
 
verbal advice & print to parents-children at home (Turissi) 
no intervention (current 
practice) 
                   
£6,700  
verbal advice - in school and at home activities children at 
school & newsletter (School) Buller 
no intervention (current 
practice) 
                 
£260,000  
verbal advice group session- uni students 
no intervention (current 
practice) 
                   
£42,000  
construction of shade sail no built shade £2,394,901  
multicomponent beach and pool none £10,621,954  
multicomponent community none £1,069,469  
multicomponent community £207,339  
multicomponent education 2-7 years(Bauer) 3 hour education £32,498,835  
multicomponent education 13-15 year olds 3 hour education £50,940,170  
multi-component healthcare - 13-15 year olds PA & diet £82,264,556  
multicomponent work setting 21065 year olds Delayed £1,298,476  
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PH33: HIV testing: increasing uptake in black africans 
 
Choice of rapid or standard testing do nothing £31,333  
Music do nothing £32,357  
Sport do nothing £30,509  
Mass media do nothing £27,566  
PH34: HIV testing: increasing uptake in MSM 
 
Choice or rapid, oral or standard testing no testing £42,632  
Opt-out intervention no testing £42,145  
Retreat intervention no testing £56,285  
Peer referral intervention no testing £50,358  
Multi-component mass media no testing £62,613  
NG55: Harmful sexual behaviour 
 
Multi-systemic therapy for problem sexual behaviours 
Cognitive behavioural 
therapy dominant  
Cognitive behavioural therapy Play therapy £2,685  
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